These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20179425)

  • 21. Immuno-oncology moves beyond PD-1.
    Sheridan C
    Nat Biotechnol; 2015 Jul; 33(7):673-5. PubMed ID: 26153987
    [No Abstract]   [Full Text] [Related]  

  • 22. Editorial: Development of Anticancer Reagents.
    Liu X
    Comb Chem High Throughput Screen; 2017; 20(5):356. PubMed ID: 29050547
    [No Abstract]   [Full Text] [Related]  

  • 23. The first of the big spenders.
    Hodgson J
    Biotechnology (N Y); 1992 Jun; 10(6):654-8. PubMed ID: 1368886
    [No Abstract]   [Full Text] [Related]  

  • 24. Academia and industry: allocating credit for discovery and development of new therapies.
    Flier JS
    J Clin Invest; 2019 May; 129(6):2172-2174. PubMed ID: 31107243
    [No Abstract]   [Full Text] [Related]  

  • 25. Biotechnology - 12th European Congress.
    Neubauer P; Mursula A
    IDrugs; 2005 Oct; 8(10):809-12. PubMed ID: 16254798
    [No Abstract]   [Full Text] [Related]  

  • 26. The role of the chemical biology core facility at EMBL: a vision for a European roadmap.
    Lewis JD
    ACS Chem Biol; 2007 Jan; 2(1):21-3. PubMed ID: 17243779
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
    Dhimolea E; Reichert JM
    MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glaxo to close top-ranked institute.
    Balter M
    Science; 1997 Oct; 278(5337):379. PubMed ID: 9381135
    [No Abstract]   [Full Text] [Related]  

  • 30. Emergence of Chinese drug discovery research: impact of hit and lead identification.
    Zhou C; Zhou Y; Wang J; Zhu Y; Deng J; Wang MW
    J Biomol Screen; 2015 Mar; 20(3):318-29. PubMed ID: 25520370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The coming of age of engineered multivalent antibodies.
    Nuñez-Prado N; Compte M; Harwood S; Álvarez-Méndez A; Lykkemark S; Sanz L; Álvarez-Vallina L
    Drug Discov Today; 2015 May; 20(5):588-94. PubMed ID: 25757598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic monoclonal antibodies: knowledge transfer from Inserm].
    Perrin-Wolff M; Cans C
    Med Sci (Paris); 2009 Dec; 25(12):1193-5. PubMed ID: 20035705
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases.
    Jones CL; Yeung BK; Manjunatha U; Shi PY; Bodenreider C; Diagana TT
    Nat Rev Drug Discov; 2015 Jun; 14(6):442-4. PubMed ID: 26027536
    [No Abstract]   [Full Text] [Related]  

  • 35. Hopes build that new infrastructure can aid drug discovery.
    Esteves B
    Nat Med; 2011 Oct; 17(10):1174-5. PubMed ID: 21988981
    [No Abstract]   [Full Text] [Related]  

  • 36. Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies.
    Chartrain M; Chu L
    Curr Pharm Biotechnol; 2008 Dec; 9(6):447-67. PubMed ID: 19075685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.
    Arnett SO; Teillaud JL; Wurch T; Reichert JM; Dunlop C; Huber M
    MAbs; 2011; 3(2):133-52. PubMed ID: 21304271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research institute and medical school to partner with international company in drug development venture.
    W V Med J; 2014; 110(5):48. PubMed ID: 25643477
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost of institute was small change to Roche.
    Christen U
    Nature; 2000 Aug; 406(6795):455. PubMed ID: 10952286
    [No Abstract]   [Full Text] [Related]  

  • 40. "But Dr. Old, we already have an antibody!" Reflections on Lloyd Old's "academic biotech" approach for targeted antibodies.
    Ritter G
    Cancer Immun; 2012; 12():9. PubMed ID: 22896754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.